CHAMPIONS ONCOLOGY, INC. Cost of Revenue
CHAMPIONS ONCOLOGY, INC. (CSBR) reported Cost of Revenue of $7.53 million for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-11.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-09-11
- CHAMPIONS ONCOLOGY, INC. cost of goods and services sold for the quarter ending 2026-07-31 was $7.53M, a 5.77% decline year-over-year.
- CHAMPIONS ONCOLOGY, INC. cost of goods and services sold for the quarter ending 2026-04-30 was $6.81M, a 6.34% decline year-over-year.
- CHAMPIONS ONCOLOGY, INC. cost of goods and services sold for the quarter ending 2026-01-31 was $8.83M, a 33.50% increase year-over-year.
- CHAMPIONS ONCOLOGY, INC. cost of goods and services sold for the quarter ending 2025-10-31 was $7.26M, a 2.23% decline year-over-year.
- CHAMPIONS ONCOLOGY, INC. cost of goods and services sold for fiscal 2026 was $30.90M, a 8.84% increase from fiscal 2025.
- CHAMPIONS ONCOLOGY, INC. cost of goods and services sold for fiscal 2025 was $28.39M, a 3.44% decline from fiscal 2024.
- CHAMPIONS ONCOLOGY, INC. cost of goods and services sold for fiscal 2024 was $29.40M, a 0.44% decline from fiscal 2023.
- CHAMPIONS ONCOLOGY, INC. cost of goods and services sold for fiscal 2023 was $29.53M, a 24.97% increase from fiscal 2022.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 3 month as first filed | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 9 month as first filed | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|---|---|
| 2026-07-31 | $7.53M 10-Q · filed 2026-09-11 | $14.34M derived: sum of 2 quarters · filed 2026-09-11 | $23.18M derived: sum of 3 quarters · filed 2026-09-11 | $30.44M derived: sum of 4 quarters · filed 2026-09-11 | ||
| 2026-04-30 | $6.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-27 | $15.64M derived: sum of 2 quarters · filed 2026-07-27 | $22.91M derived: sum of 3 quarters · filed 2026-07-27 | $30.90M 10-K · filed 2026-07-27 | ||
| 2026-01-31 | $8.83M 10-Q · filed 2026-03-12 | $16.10M derived: sum of 2 quarters · filed 2026-03-12 | $24.09M 10-Q · filed 2026-03-12 | $31.36M derived: sum of 4 quarters · filed 2026-09-11 | ||
| 2025-10-31 | $7.26M 10-Q · filed 2025-12-15 | $15.26M 10-Q · filed 2025-12-15 | $22.53M derived: sum of 3 quarters · filed 2026-09-11 | $29.14M derived: sum of 4 quarters · filed 2026-09-11 | ||
| 2025-07-31 | $8.00M 10-Q · filed 2026-09-11 | $15.27M derived: sum of 2 quarters · filed 2026-09-11 | $21.88M derived: sum of 3 quarters · filed 2026-09-11 | $29.31M derived: sum of 4 quarters · filed 2026-09-11 | ||
| 2025-04-30 | $7.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-27 | $13.89M derived: sum of 2 quarters · filed 2026-07-27 | $21.32M derived: sum of 3 quarters · filed 2026-07-27 | $28.39M 10-K · filed 2026-07-27 | ||
| 2025-01-31 | $6.62M 10-Q · filed 2026-03-12 | $14.04M derived: sum of 2 quarters · filed 2026-03-12 | $21.12M 10-Q · filed 2026-03-12 | $28.37M derived: sum of 4 quarters · filed 2026-03-12 | ||
| 2024-10-31 | $7.43M 10-Q · filed 2025-12-15 | $14.50M 10-Q · filed 2025-12-15 | $21.75M derived: sum of 3 quarters · filed 2025-12-15 | $29.60M derived: sum of 4 quarters · filed 2025-12-15 | ||
| 2024-07-31 | $7.07M 10-Q · filed 2025-09-15 | $14.32M derived: sum of 2 quarters · filed 2025-09-15 | $22.17M derived: sum of 3 quarters · filed 2025-09-15 | $28.79M derived: sum of 4 quarters · filed 2025-09-15 | ||
| 2024-04-30 | $7.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-07-23 | $15.10M derived: sum of 2 quarters · filed 2025-07-23 | $21.72M derived: sum of 3 quarters · filed 2025-07-23 | $29.40M 10-K · filed 2025-07-23 | ||
| 2024-01-31 | $7.85M 10-Q · filed 2025-03-17 | $14.47M derived: sum of 2 quarters · filed 2025-03-17 | $22.15M 10-Q · filed 2025-03-17 | $29.49M derived: sum of 4 quarters · filed 2025-03-17 | ||
| 2023-10-31 | $6.62M 10-Q · filed 2024-12-16 | $14.30M 10-Q · filed 2024-12-16 | $21.64M derived: sum of 3 quarters · filed 2024-12-16 | $29.34M derived: sum of 4 quarters · filed 2024-12-16 | ||
| 2023-07-31 | $7.68M 10-Q · filed 2024-09-13 | $15.02M derived: sum of 2 quarters · filed 2024-09-13 | $22.72M derived: sum of 3 quarters · filed 2024-09-13 | $30.16M derived: sum of 4 quarters · filed 2024-09-13 | ||
| 2023-04-30 | $7.34M derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-19 | $15.04M derived: sum of 2 quarters · filed 2024-07-19 | $22.48M derived: sum of 3 quarters · filed 2024-07-19 | $29.53M 10-K · filed 2024-07-19 | ||
| 2023-01-31 | $7.70M 10-Q · filed 2024-03-15 | $15.14M derived: sum of 2 quarters · filed 2024-03-15 | $22.19M 10-Q · filed 2024-03-15 | $28.41M derived: sum of 4 quarters · filed 2024-03-15 | ||
| 2022-10-31 | $7.44M 10-Q · filed 2023-12-13 | $14.49M 10-Q · filed 2023-12-13 | $20.72M derived: sum of 3 quarters · filed 2023-12-13 | $27.12M derived: sum of 4 quarters · filed 2023-12-13 | ||
| 2022-07-31 | $7.05M 10-Q · filed 2023-09-13 | $13.27M derived: sum of 2 quarters · filed 2023-09-13 | $19.68M derived: sum of 3 quarters · filed 2023-09-13 | $25.29M derived: sum of 4 quarters · filed 2023-09-13 | ||
| 2022-04-30 | $6.22M derived: 10-K 12 month − 10-Q 9 month · filed 2023-07-24 | $12.63M derived: sum of 2 quarters · filed 2023-07-24 | $18.24M derived: sum of 3 quarters · filed 2023-07-24 | $23.63M 10-K · filed 2023-07-24 | ||
| 2022-01-31 | $6.41M 10-Q · filed 2023-03-16 | $12.02M derived: sum of 2 quarters · filed 2023-03-16 | $17.41M 10-Q · filed 2023-03-16 | $23.25M derived: sum of 4 quarters · filed 2023-03-16 | ||
| 2021-10-31 | $5.61M 10-Q · filed 2022-12-13 | $11.01M 10-Q · filed 2022-12-13 | $16.85M derived: sum of 3 quarters · filed 2022-12-13 | $21.47M derived: sum of 4 quarters · filed 2022-12-13 | ||
| 2021-07-31 | $5.40M 10-Q · filed 2022-09-12 | $11.24M derived: sum of 2 quarters · filed 2022-09-12 | $15.86M derived: sum of 3 quarters · filed 2022-09-12 | $21.51M derived: sum of 4 quarters · filed 2022-09-12 | ||
| 2021-04-30 | $5.84M derived: 10-K 12 month − 10-Q 9 month · filed 2022-07-22 | $10.47M derived: sum of 2 quarters · filed 2022-07-22 | $16.11M derived: sum of 3 quarters · filed 2022-07-22 | $21.45M 10-K · filed 2022-07-22 | ||
| 2021-01-31 | $4.62M 10-Q · filed 2022-03-15 | $4.84M 10-Q · filed 2021-03-15 | $10.27M derived: sum of 2 quarters · filed 2022-03-15 | $15.60M 10-Q · filed 2022-03-15 | $15.82M 10-Q · filed 2021-03-15 | $20.64M derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-10-31 | $5.64M 10-Q · filed 2021-12-13 | $10.98M 10-Q · filed 2021-12-13 | $16.02M derived: sum of 3 quarters · filed 2021-12-13 | $20.35M derived: sum of 4 quarters · filed 2021-12-13 | ||
| 2020-07-31 | $5.34M 10-Q · filed 2021-09-13 | $10.38M derived: sum of 2 quarters · filed 2021-09-13 | $14.70M derived: sum of 3 quarters · filed 2021-09-13 | $18.58M derived: sum of 4 quarters · filed 2021-09-13 | ||
| 2020-04-30 | $5.04M derived: 10-K 12 month − 10-Q 9 month · filed 2021-07-26 | $9.37M derived: sum of 2 quarters · filed 2021-07-26 | $13.25M derived: sum of 3 quarters · filed 2021-07-26 | $17.00M 10-K · filed 2021-07-26 | ||
| 2020-01-31 | $4.33M 10-Q · filed 2021-03-15 | $8.21M derived: sum of 2 quarters · filed 2021-03-15 | $11.96M 10-Q · filed 2021-03-15 | |||
| 2019-10-31 | $3.88M 10-Q · filed 2020-12-14 | $7.63M 10-Q · filed 2020-12-14 | ||||
| 2019-07-31 | $3.75M 10-Q · filed 2020-09-14 | |||||
| 2019-01-31 | $3.43M 10-Q · filed 2020-03-16 | $6.88M derived: sum of 2 quarters · filed 2020-03-16 | $9.96M 10-Q · filed 2020-03-16 | |||
| 2018-10-31 | $3.45M 10-Q · filed 2019-12-16 | $6.53M 10-Q · filed 2019-12-16 | ||||
| 2018-07-31 | $3.08M 10-Q · filed 2019-09-16 | |||||
| 2018-01-31 | $2.47M 10-Q · filed 2019-03-18 | $5.13M derived: sum of 2 quarters · filed 2019-03-18 | $7.74M 10-Q · filed 2019-03-18 | |||
| 2017-10-31 | $2.65M 10-Q · filed 2018-12-17 | $5.29M 10-Q · filed 2018-12-17 | ||||
| 2017-07-31 | $2.64M 10-Q · filed 2018-09-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |